Celltrion Pharm Inc (068760) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Celltrion Pharm Inc stock KRW 44,385, price KRW 39,600, upside +12.1%, quality 65 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 36,500 KRW – 143,662 KRW · fair‑value band 31,070 KRW – 57,701 KRW · the 39,600 KRW price screens below the 44,385 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Celltrion Pharm in your weekly email
Every Wednesday you see whether Celltrion Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea.
Show moreShow less
The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies.
Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operates as a subsidiary of Celltrion, Inc.
Stock analysis
Celltrion Pharm Inc (068760) currently trades at 39,600 KRW, while our model-based Fair Value estimate is 44,385 KRW, implying the stock looks roughly 11% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 32,680 KRW per share, and 2 of the 24 models we run sit above the 39,600 KRW price.
Bear case: the Economic Profit group reads lowest at 10,606 KRW, and 22 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 31,070 KRW (bear) to 57,701 KRW (bull), the price of 39,600 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Celltrion Pharm Inc reported revenue of 536B KRW in FY2025 versus 399B KRW in FY2021, a compound +7.7%/yr. Reported net income was 38.8B KRW in FY2025, compounding +2.9%/yr from FY2021.
Key figures
Market cap 1.8T KRW (≈ $1.3B) Small · P/E ratio 66.3 · P/S ratio 6.39 · EPS (TTM) 588.05 KRW · Dividend yield 0.5% · Net margin 9.5% · Return on equity 8.9% · Return on assets (EBIT) 6.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 12%, 068760 screens cheaper than that median.
Fair Value models
Bear31,070 KRWFair Value 44,385 KRWBull57,701 KRW
Price 39,600 KRW · Upside +12.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (331.70 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Start year 2020 (pandemic). Over 10 years: +21.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+0.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.0%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.9.4% vs 27.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 11%
2025 sits 73% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +16.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+12.1% · Above median
Profitability
Return on equity (12 months)8.9% · Above median
Return on assets5.1% · Above median
Net margin (12 months)9.5% · Above median
Operating margin (12 months)11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)92.7% · Top 25%
Dividend yield (12 months)0.5% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)66.3× · Priciest 25%
P/B4.02× · Priciest 25%
P/S (12 months)6.39× · Priciest 25%
Price / free cash flow (fiscal year)25.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Celltrion Pharm Inc (068760) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 44,385 KRW versus a price of 39,600 KRW, about +12% upside (undervalued).
What is the fair value of 068760?
Our model-based fair value for Celltrion Pharm Inc is 44,385 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 39,600 KRW.
What is the quality score of 068760?
Celltrion Pharm Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Celltrion Pharm Inc (068760)?
Our model-based price target is the fair value of 44,385 KRW (as of Nov 6, 2026) from 24 valuation models. Cautious scenario 31,070 KRW, optimistic scenario 57,701 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Celltrion Pharm Inc stock forecast for 2026?
Our models put fair value at 44,385 KRW, about +12% upside versus a price of 39,600 KRW (undervalued). Cautious scenario 31,070 KRW, optimistic scenario 57,701 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Celltrion Pharm Inc (068760)?
Celltrion Pharm Inc reported trailing-twelve-month revenue of about 275B KRW (latest available figure, as of Nov 6, 2026).
Does Celltrion Pharm Inc pay a dividend?
Celltrion Pharm Inc currently shows a dividend yield of 0.51% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Celltrion Pharm Inc (068760) and when is the ex-dividend date?
Celltrion Pharm Inc pays a dividend of 200.00 KRW per share a year, a dividend yield of 0.5%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 34.0% of earnings. Free cash flow covers the dividend 7.74 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Celltrion Pharm Inc (068760)?
For today's price to be fair in a discounted-cash-flow model, Celltrion Pharm Inc would have to grow free cash flow by +19.1 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 068760 use?
Our models discount Celltrion Pharm Inc at 11.3 %: a base by market capitalisation (small), damped by beta 0.90, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Celltrion Pharm Inc that is +19.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.3 %) and the same formula as our fair value.
How much growth has Celltrion Pharm Inc (068760) delivered so far?
Over the past 5 years revenue at Celltrion Pharm Inc grew +18.1 % a year. The price currently implies free-cash-flow growth of +19.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Celltrion Pharm Inc (068760) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Celltrion Pharm Inc (+19.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Celltrion Pharm Inc (068760)?
The free-cash-flow yield on the price is 3.91 %: that much free cash flow Celltrion Pharm Inc produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Celltrion Pharm Inc (068760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Celltrion Pharm Inc it is 44,385 KRW per share (as of Nov 6, 2026), against a price of 39,600 KRW. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Celltrion Pharm Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 068760 trades below its calculated fair value: price 39,600 KRW, fair value 44,385 KRW, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 068760?
No. The price is what the market pays today (39,600 KRW); the fair value is what the company's own numbers justify (44,385 KRW). For Celltrion Pharm Inc the two are 4,785 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Celltrion Pharm Inc worth?
The market values Celltrion Pharm Inc at about 1.8T KRW (market capitalisation, as of Nov 6, 2026). Per share that is 39,600 KRW; our models calculate a fair value of 44,385 KRW per share.
What do the bullish and bearish scenarios say about 068760?
Our models span a range for Celltrion Pharm Inc: cautious scenario 31,070 KRW, base 44,385 KRW, optimistic 57,701 KRW per share (as of Nov 6, 2026, price 39,600 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 068760?
Celltrion Pharm Inc trades at a price-to-earnings ratio of 66.3 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 44,385 KRW is built from several models across several years. Other multiples: P/B 4.0, P/S 6.4, EV/EBITDA 39.8.
How solid is the balance sheet of Celltrion Pharm Inc (068760)?
Balance-sheet figures for Celltrion Pharm Inc (as of Nov 6, 2026): return on equity 8.9%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 068760 from its 52-week high?
Celltrion Pharm Inc trades at 39,600 KRW, about 48% below its 52-week high of 75,700 KRW and 8% above the low of 36,500 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 44,385 KRW is for.
Which stocks are comparable to Celltrion Pharm Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Celltrion Pharm Inc stock attractive at the current price?
The data as of Nov 6, 2026: price 39,600 KRW, calculated fair value 44,385 KRW (+12%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 068760 calculated?
We run Celltrion Pharm Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 44,385 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Celltrion Pharm Inc currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Celltrion Pharm Inc (068760)?
The closing price on Nov 6, 2026 was 39,600 KRW. Our model-based fair value is 44,385 KRW, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Celltrion Pharm Inc right now?
A fairly wide model range (31,070 KRW to 57,701 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Celltrion Pharm Inc
How large is the market capitalisation of Celltrion Pharm Inc (068760)?
The market capitalisation of Celltrion Pharm Inc is 1.8T KRW (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Celltrion Pharm Inc (068760)?
The price-to-sales ratio of Celltrion Pharm Inc is 6.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Celltrion Pharm Inc (068760)?
Earnings per share at Celltrion Pharm Inc are 588.05 KRW (price ÷ EPS = P/E 66.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Celltrion Pharm Inc (068760)?
The dividend yield of Celltrion Pharm Inc is 0.5% (payout 34.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Celltrion Pharm Inc (068760)?
The net margin of Celltrion Pharm Inc is 9.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Celltrion Pharm Inc (068760)?
The return on equity (ROE) of Celltrion Pharm Inc is 8.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Celltrion Pharm Inc (068760)?
On an EBIT basis the return on assets of Celltrion Pharm Inc is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Celltrion Pharm Inc (068760)?
The operating margin of Celltrion Pharm Inc is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Celltrion Pharm Inc (068760)?
Revenue at Celltrion Pharm Inc is growing +92.7% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Celltrion Pharm Inc (068760)?
Earnings per share at Celltrion Pharm Inc are growing +226% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Celltrion Pharm Inc (068760) carry?
The net debt of Celltrion Pharm Inc is 92.1B KRW (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Celltrion Pharm Inc in the live analysis
One click puts Celltrion Pharm Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026